Publication: Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis
Issued Date
2014-01-01
Resource Type
ISSN
1532866X
00490172
00490172
Other identifier(s)
2-s2.0-84919597136
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Seminars in Arthritis and Rheumatism. Vol.44, No.3 (2014), 366-370
Suggested Citation
Patompong Ungprasert, Anawin Sanguankeo, Sikarin Upala, Eric L. Knight Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. Vol.44, No.3 (2014), 366-370. doi:10.1016/j.semarthrit.2014.06.004 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/34709
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: A systematic review and meta-analysis
Other Contributor(s)
Abstract
© 2014 Elsevier Inc. Objective: To investigate the association between giant cell arteritis (GCA)/polymyalgia rheumatica (PMR) and malignancy risk. Methods: We conducted a systematic review and meta-analysis of cohort studies that reported relative risk, hazard ratio, or standardized incidence ratio (SIRs) with 95% confidence comparing malignancy risk in patients with GCA/PMR versus non-GCA/PMR participants. Pooled risk ratios and 95% confidence intervals were calculated using a random-effect, generic inverse variance method. Result: A total of six studies were identified and included in our data analysis. The pooled risk ratio of malignancy in patients with GCA/PMR was 1.14 (95% CI: 1.05-1.22). The risk was higher in the first 6-12 months after diagnosis with the pooled risk ratio of 2.16 (95% CI: 1.85-2.53). However, when we performed a sensitivity analysis that excluded one study with a potential selection bias, the pooled risk ratio decreased and did not achieve statistical significance. Conclusion: Our study demonstrated a low but statistically significant increased malignancy risk among patients with GCA/PMR. However, when we excluded one study with potential selection bias, the new pooled risk ratio did not achieve statistical significance.